European study of real-life haemophilia treatment emphasizes need to improve standard of care
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announces the results from a new European study that assessed the efficacy of haemophilia care in real life. The study, which was fully funded by Sobi, showed that treatment practice varied widely between countries and that patients treated on-demand and prophylactically both experienced bleeds, emphasizing the need for further enhancing standard of care. The authors concluded that prophylaxis should be considered for people with frequent bleeds to avoid pain and deterioration of joint function, and the